CD4 and small cell lung carcinoma: Additionally, Schmälter et al. observed in 32 SCLC patients receiving atezolizumab combined with chemotherapy that patients with reduced central memory CD4+ T cells (CD62L+ CD45RA- CD4+ T) or Th17 subsets (CD4+CXCR3–CCR4+CCR5- CCR6+ T) after two treatment cycles had longer cumulative survival [95].